Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jim Cregg"'
Autor:
Schulze, Christopher J., Seamon, Kyle J., Yulei Zhao, Yang, Yu C., Jim Cregg, Dongsung Kim, Tomlinson, Aidan, Choy, Tiffany J., Zhican Wang, Ben Sang, Pourfarjam, Yasin, Lucas, Jessica, Cuevas-Navarro, Antonio, Ayala-Santos, Carlos, Vides, Alberto, Chuanchuan Li, Marquez, Abby, Mengqi Zhong, Vemulapalli, Vidyasiri, Weller, Caroline
Publikováno v:
Science; 8/18/2023, Vol. 381 Issue 6659, p794-799, 6p, 4 Diagrams
Autor:
Elena S. Koltun, Meghan A. Rice, W. Clay Gustafson, David Wilds, Jingjing Jiang, Bianca J. Lee, Zhengping Wang, Stephanie Chang, Mike Flagella, Yunming Mu, Nuntana Dinglasan, Nicole Nasholm, James W. Evans, Yingyun Wang, Kyle Seamon, Yang Liu, Cristina Blaj, John Knox, Rebecca Freilich, Elsa Quintana, Jim Cregg, Alun Bermingham, Adrian L. Gill, Jacqueline Am Smith, Mallika Singh
Publikováno v:
Cancer Research. 82:3597-3597
Mutant RAS is common in pancreatic carcinoma (PDAC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) and exists predominantly in the GTP-bound (RAS(ON)) state, leading to excessive downstream oncogenic signaling. KRASG12C(OFF) inhibito
Autor:
Christopher J. Schulze, Jim Cregg, Kyle J. Seamon, Yu Chi Yang, Zhican Wang, Lindsay S. Garrenton, Alun Bermingham, John E. Knox, Aidan Tomlinson, Kang-Jye Chou, Shaoling Li, David P. Wildes, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Robert J. Nichols, Jacqueline A. Smith
Publikováno v:
Cancer Research. 82:3598-3598
The clinical activity of KRASG12C(OFF) inhibitors has validated KRASG12C as an oncogenic driver in human cancers and demonstrated the power of targeting cysteine mutations with covalent inhibitors. A second oncogenic RAS cysteine mutation, KRASG13C,
Autor:
W. Clay Gustafson, David Wildes, Meghan A. Rice, Bianca J. Lee, Jingjing Jiang, Zhengping Wang, Stephanie Chang, Mike Flagella, Yunming Mu, Nuntana Dinglasan, Nicole Nasholm, James W. Evans, Kyle Seamon, Jim Cregg, Alun Bermingham, Rebecca Freilich, Adrian L. Gill, Elena Koltun, Jacqueline A Smith, Mallika Singh
Publikováno v:
Journal of Clinical Oncology. 40:591-591
591 Background: RAS proteins (such as KRAS, NRAS, HRAS) are small GTPases that drive cell proliferation and survival when bound to GTP. Mutant RAS proteins exist predominantly in the GTP-bound (RAS(ON)) state, leading to excessive downstream signalin
Autor:
Lindsay S. Garrenton, Denise Reyes, Zhican Wang, Jacqueline Smith, Jingjing Jiang, Elena S. Koltun, David Wildes, Mallika Singh, Kyle Seamon, Daniel M. Whalen, Adrian Liam Gill, Tiffany J. Choy, Alun Bermingham, Michael P. Longhi, Shaoling Li, Mayra Rios, Robert J. Nichols, Kang-Jye Chou, Jim Cregg, Christopher J. Schulze, Rich Hansen, John E. Knox, Kevin C. Yang
Publikováno v:
Cancer Research. 81:1261-1261
The KRASG12C mutation is found in 11% of non-small cell lung cancers and 4% of colorectal cancers. Recently, a class of KRASG12C(OFF) inhibitors has shown promising activity in patients whose cancers bear KRASG12C. These data validate KRASG12C as an
Autor:
Yang Liu, Alun Bermingham, Elena S. Koltun, Cristina Blaj, Jacqueline Smith, Stephanie S. Chang, Bianca J. Lee, Kang-Jye Chou, Richard Hansen, Laura L. McDowell, Kyle Seamon, Meghan A. Rice, Jim Cregg, Jun Huang, John E. Knox, Adrian Liam Gill, Daniel M. Whalen, David Wildes, Zhengping Wang, Jay Dinglasan, Jingjing Jiang, Rebecca Freilich, Mallika Singh
Publikováno v:
Cancer Research. 81:1260-1260
KRASG12V mutant cancers represent a significant unmet medical need with nearly 44,000 new diagnoses annually in the US. The KRASG12V mutation occurs frequently in multiple tumor histotypes; the incidence in NSCLC, CRC and pancreatic cancers is 6%, 10